Status:
UNKNOWN
Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach
Lead Sponsor:
University Hospital Tuebingen
Conditions:
Genetic Predisposition
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Reaction of the immune system and the body to a Coronavirus-19 (COVID-19) vaccination is so different and ultimately unpredictable has not yet been clarified. It is also not yet known why people who h...
Detailed Description
Various vaccines against COVID-19 ("CORONA") have now been approved in Germany. How and why the reaction of the immune system and the body to a COVID-19 vaccination is so different and ultimately unpr...
Eligibility Criteria
Inclusion
- Group 1
- Healthy donors (HD) who had recovered from COVID-19 disease and/or HD who did not have COVID-19 disease in the past
- and who will receive the COVID-19 vaccine or a COVID19 vaccine candidate or other protective vaccines
- HD who did receive one dose of a specific COVID19 vaccine but who will receive a different vac-cine for her/his second vaccination for completion of the immunization
- Age \> 18 years
- Group 2
- Vaccinated subjects who are diagnosed with central thrombosis, anaphylactic shock or other major or minor complications such as atopic dermatitis (for example) after vaccination.
- Age \> 18 years
Exclusion
- Group 1 and 2
- \- Missing informed consent of the subject
Key Trial Info
Start Date :
June 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2024
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04873128
Start Date
June 10 2021
End Date
July 1 2024
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Tübingen
Tübingen, Germany, 72076